PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests

2013-02-05
(Press-News.org) STANFORD, Calif. - An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford University School of Medicine.

The effect remains even when the cancer cells have become resistant to other treatments, and the findings may one day provide a glimmer of hope for people with the cancer, known as gastrointestinal stromal tumor, or GIST. The scientists hope to move into human clinical trials of the antibody within two years.

The antibody's target is a receptor called KIT, which is often mutated in patients with the cancer. When mutated, KIT sends a continuous stream of messages into the cell urging it to grow uncontrollably. The Stanford researchers found that the antibody reduces the amount of KIT on the surface of the cancer cells and stimulates immune cells called macrophages to kill the rogue cells.

Currently, people with GIST are often treated first with surgery and then with the drug imatinib, marketed as Gleevec - a small molecule that also targets KIT. The treatment, which was approved for GIST in 2002, has been remarkably successful: It has increased the average survival time of many people with advanced disease from about 18 months to about five years. It was the first targeted small molecule inhibitor that proved effective against a solid tumor, but its effect is temporary.

"Gleevec, or imatinib, marked a paradigm shift in our understanding about cancer treatment and sparked much additional research into these inhibitors," said Matt van de Rijn, MD, PhD, professor of pathology. "However, a new mutation almost always occurs over time in KIT that renders the tumor insensitive to the drug. We've found that treatment of these resistant cells with an antibody targeting KIT slows the growth of human GIST cells in cell culture and in animals, and increases their chances of being removed by the immune system."

The researchers believe it may be possible that the anti-KIT antibody treatment could be used as an alternative to, or even in combination with, imatinib or other small-molecule or antibody-based therapies to provide better control of the cancer.

"We're moving from an era in which, historically, patients are often treated with a single agent or class of agents into a time when tumors might be treated with more than one approach from the moment of diagnosis," said van de Rijn.

He is a co-senior author of the study, which will be published online Feb. 4 in the Proceedings of the National Academy of Sciences. Irving Weissman, MD, director of Stanford's Institute for Stem Cell Biology and Regenerative Medicine, is the other co-senior author. Former graduate student Badreddin Edris, PhD, postdoctoral scholar Stephen Willingham, PhD, and graduate student Kipp Weiskopf share first authorship of the paper. Weissman is also a member of Stanford's Cancer Institute.

About 3,000 to 6,000 people per year are diagnosed with GIST in the United States. Seventy to 80 percent of these cancers have what's called an activating mutation in the cell surface receptor called KIT. This mutation causes the receptor to bombard the cells with the signal to proliferate and drives tumor growth. Although imantinib binds to KIT and inactivates its signaling - resulting in the temporary control of the disease in about 80 percent of cases - the receptor will nearly always develop a new mutation that renders it resistant to the small molecule.

Researchers in the van de Rijn and Weissman labs used cancer cell lines isolated from three patients with GIST for their study: Two were from patients whose tumors had become resistant to imatinib, and one was from a patient whose tumor was still sensitive to the treatment. They also used a cancer cell line from a patient with an unrelated cancer, called a leiomyosarcoma, as a control.

When they treated the cancer cells in a laboratory dish with the anti-KIT antibody, called SR1, the researchers found that the GIST tumor cells grew significantly more slowly than did the control cancer cells, regardless of their sensitivity or resistance to imatinib. When they investigated more closely, they found that the tumor cells exposed to the anti-KIT antibody expressed less KIT on their surface than did untreated cells. Furthermore, all three of the antibody-treated GIST cell lines were significantly more likely to be enveloped and destroyed by a type of immune cell called a macrophage than were untreated or control cancer cells.

To confirm their findings, the researchers genetically engineered the three GIST tumor cell lines to express proteins that emit colored light under certain conditions. This allowed them to track the growth and location of the cells in living laboratory animals over time. They injected the engineered cells into the abdominal cavities of mice, waited two weeks for the cancer cells to become established and then treated the animals with the anti-KIT antibody.

"Although the tumors from the imatinib-resistant cell lines continued to grow, their growth rate was reduced by about 10-fold when compared to that observed in untreated animals," said van de Rijn.

The researchers are now planning to investigate whether a combination treatment of anti-KIT plus imatinib, or anti-KIT plus an antibody that targets a cell-surface molecule called CD47 previously identified in Weissman's laboratory, will further inhibit tumor growth. (Anti-CD47 treatment has been shown to block a "don't eat me" signal expressed by many types of cancer cells that protects them against macrophages.)

Coupling anti-CD47 with another treatment such as anti-KIT that appears to enhance the engulfment of the cancer cells by macrophages may provide a synergistic effect against the tumor, the researchers believe. A similar approach was shown to cure aggressive non-Hodgkin's lymphoma in mice in Weissman's lab in 2010.

### Other Stanford researchers involved in the study include postdoctoral scholar Anne Volkmer, MD; instructor Jens-Peter Volkmer, MD; technician Kelli Montgomery; research assistant Humberto Contreras-Trujillo; former medical student Agnieszka Czechowicz, MD, PhD; and associate professor of pathology Robert West, MD, PhD.

The research was supported by the National Institutes of Health (grant CA 112270), the Life Raft Group, the GIST Cancer Research Fund and the Ludwig Institute for Cancer Research. The research was dedicated to the memory of Angela Lee, PhD, a colleague of many of the authors who lost her life to GIST in 2011.

Information about Stanford's Department of Pathology, which also supported the work, is available at http://pathology.stanford.edu/.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html.


ELSE PRESS RELEASES FROM THIS DATE:

USC scientists design mouse with more human-like immune response

2013-02-05
LOS ANGELES — Medical scientists at the University of Southern California (USC) have bred a first-of-its-kind mouse model that possesses an immune response system more like a human's. The discovery makes way for quicker and more cost-effective development of next-generation drugs to treat human diseases like cancer, diabetes and tuberculosis. Medical researchers have long used mice and rats to help formulate new drugs and vaccines, in part because their genetic and biological characteristics closely parallel human physiology. But mice are not humans, and many experimental ...

Cells predict onset of graft-versus-host disease in men receiving BMTs from female donors

2013-02-05
STANFORD, Calif. — Stanford University School of Medicine investigators have identified a clutch of cells that — if seen in a male patient's blood after receiving a brand-new immune system in the form of a bone-marrow transplant from a female donor — herald the onset of chronic graft-versus-host disease, or cGVHD. In this devastating syndrome, the patient's tissues come under a vicious and enduring assault by the transplanted cells. "The overwhelming majority of patients who have these cells in their blood either have or will develop cGVHD within one to three months," ...

3D printing breakthrough with human embryonic stem cells

2013-02-05
A team of researchers from Scotland has used a novel 3D printing technique to arrange human embryonic stem cells (hESCs) for the very first time. It is hoped that this breakthrough, which has been published today, 5 February, in the journal Biofabrication, will allow three-dimensional tissues and structures to be created using hESCs, which could, amongst other things, speed up and improve the process of drug testing. In the field of biofabrication, great advances have been made in recent years towards fabricating three-dimensional tissues and organs by combining artificial ...

'Default' options influence patient choices in advance care directives, Penn study shows

2013-02-05
PHILADELPHIA – Advance care directives allow patients to provide instructions about their preferences for the care they would like to receive if they develop an illness or a life-threatening injury and lose the capacity to make decisions for themselves. While many people may assume that patients have strong preferences for the type and aggressiveness of care they wish to receive near life's end, a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania suggests that for many patients, preferences for end-of-life care are constructed ...

Experimental therapy crosses blood-brain barrier to treat neurological disease

2013-02-05
CINCINNATI – Researchers have overcome a major challenge to treating brain diseases by engineering an experimental molecular therapy that crosses the blood-brain barrier to reverse neurological lysosomal storage disease in mice. Posted online in PNAS Early Edition on Feb. 4, the study was led by scientists at Cincinnati Children's Hospital Medical Center. "This study provides a non-invasive procedure that targets the blood-brain barrier and delivers large-molecule therapeutic agents to treat neurological lysosomal storage disorders," said Dao Pan, PhD, principal investigator ...

Body language can predict outcomes for recovering alcoholics

2013-02-05
To predict whether a problem drinker will hit the bottle again, ignore what they say and watch their body language for displays of shame, a University of British Columbia study finds. The study, which explored drinking and health outcomes in newly sober recovering alcoholics, is the first to show that physical manifestations of shame – from slumped shoulders to narrow chests – can directly predict a relapse in people who struggle with substances. "Our study finds that how much shame people display can strongly predict not only whether they will go on to relapse, but ...

20 hours of TV a week almost halves sperm count

2013-02-05
Healthy young men who watch TV for more than 20 hours a week have almost half the sperm count of men who watch very little TV, indicates a study published online in the British Journal of Sports Medicine. Conversely, men who do 15 or more hours of moderate to vigorous exercise every week have sperm counts that are 73% higher than those who exercise little, the findings show. Semen quality seems to have deteriorated over the past few decades, although it's not clear why, say the authors. To find out if an increasingly sedentary lifestyle might be a contributory ...

The last Neanderthals of southern Iberia did not coexist with modern humans

The last Neanderthals of southern Iberia did not coexist with modern humans
2013-02-05
The theory that the last Neanderthals –Homo neanderthalensis– persisted in southern Iberia at the same time that modern humans –Homo sapiens– advanced in the northern part of the peninsula, has been widely accepted by the scientific community during the last twenty years. An international study, in which researchers of the Spanish National Distance Education University (UNED) participate, questions this hypothesis. "It is improbable that the last Neanderthals of central and southern Iberia would have persisted until such a late date, approximately 30,000 years ago, as ...

Mutations in ASXL3 cause problems similar to Bohring-Opitz syndrome

2013-02-05
Mutations which affect the gene ASXL3 cause a novel syndrome similar to Bohring-Opitz syndrome, finds a study published in BioMed Central's open access journal Genome Medicine. This molecular definition distinguishes these children from those with Bohring-Opitz, and other similar syndromes, and highlights a technique able to help define rare diseases. When Dr Ropers from the Max-Planck Institute for Molecular Genetics in Berlin found a child with non-specific symptoms, including small size at birth, difficulties with movement and feeding, severe intellectual disability, ...

Researchers pioneer treatment for viral infection common in children

2013-02-05
Researchers at Imperial College London have discovered a new way in which a very common childhood disease could be treated. In the first year of life, 65 per cent of babies get infected by Respiratory Syncytial Virus (RSV). This causes bronchiolitis, and is thought to kill nearly 200,000 children every year worldwide. In 1966 and 1967, vaccines were tested for RSV. These had disastrous effects on the immune response, leading to a worsening of the disease and, in many cases, death. Scientists have so far not been able to fully explain this effect, which continues to ...

LAST 30 PRESS RELEASES:

Sinuses prevented prehistoric croc relatives from deep diving

Spirited away: Key protein aids transport within plant cells

Britain’s brass bands older than we thought and invented by soldiers from the Napoleonic Wars, new study reveals

The Lancet: Health threats of climate change reach record-breaking levels, as experts call for trillions of dollars spent on fossil fuels to be redirected towards protecting people’s health, lives and

‘Weekend warrior’ exercise pattern may equal more frequent sessions for lowering cognitive decline risk

Physical activity of any intensity linked to lower risk of death after dementia diagnosis

Brain changes seen in lifetime cannabis users may not be causal

For the love of suckers: Volunteers contribute to research on key freshwater fishes

Bill and Mary Anne Dingus commit $1M to fund Human Impacts on the Earth Fund at Rice

Most patients can continue GLP-1 anti-obesity drugs before surgery

Computational tool developed to predict immunotherapy outcomes for patients with metastatic breast cancer

Cerebral embolic protection by geographic region

12 new Oriental weevil species discovered using advanced imaging tools

Ultrasound can be used as search and rescue tool for the brain

Department of Defense funds study of gene therapy for muscular degeneration

People’s exposure to toxic chemicals declined in the U.S. following listing under California law

Trauma, homelessness afflict gender affirming care patients at higher rates

New $5 million DoE award supports KU startup’s green hydrogen energy research

A navigation system for microswimmers

Study finds early TAVR can be beneficial for patients with asymptomatic severe aortic stenosis

Implantable microparticles can deliver two cancer therapies at once

Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis falls short of expected benefits

The surprising reason a classical computer beat a quantum computer at its own game

Researchers Aim To Get Leg Up on Bone Repair with 3D-Printed Femur

Transforming patient care: study finds bedside interdisciplinary rounds boost satisfaction for patients and providers

Radioprotective effects of licochalcone B: DNA protection, cytokine inhibition, and antioxidant boost

Complete response to encorafenib + binimetinib in BRAF V600E-mutant tumor

Gold bugs: Spectacular new fossil arthropod preserved in fool’s gold

Optimal standing positions and ventilation in airport smoking lounges

Ancient gene influences immunity of First Nations Peoples of Oceania

[Press-News.org] Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests